Skip to content

Price / book at other companies

Amgen logo
AmgenAMGN
20.6×-6.3×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
25.2×+15.2×
Biogen logo
BiogenBIIB
1.4×+0.3×
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
3.9×-0.5×
Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Calculated from Jazz Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's price / book?
Jazz Pharmaceuticals (JAZZ) reported price / book of 2.6× in Q1 2026.
How has Jazz Pharmaceuticals's price / book changed year-over-year?
Jazz Pharmaceuticals's price / book increased by 42.2% year-over-year, from 1.8× to 2.6×.
What is the long-term trend for Jazz Pharmaceuticals's price / book?
Over 5 years (2020 to 2025), Jazz Pharmaceuticals's price / book has grown at a -2.9% compound annual growth rate (CAGR), from 2.8× to 2.4×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.